会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明申请
    • NOVEL TRANSFERASE AND AMYLASE, PROCESS FOR PRODUCING THE ENZYMES,USE THEREOF, AND GENE CODING FOR THE SAME
    • 新型转移酶和淀粉酶,生产酶的方法,用途及其基因编码
    • WO1995034642A1
    • 1995-12-21
    • PCT/JP1995001189
    • 1995-06-14
    • KIRIN BEER KABUSHIKI KAISHAKATO, MasaruMIURA, YutakaKETTOKU, MasakoIWAMATSU, AkihiroKOBAYASHI, KazuoKOMEDA, Toshihiro
    • KIRIN BEER KABUSHIKI KAISHA
    • C12N09/10
    • C12N9/2411C12N9/1048C12N9/2408C12N9/2414C12N9/2417C12P19/14
    • The invention provides a novel transferase that acts on a saccharide, as a substrate, composed of at least three sugar units wherein at least three glucose residues on the reducing end side are linked alpha -1,4 so as to transfer the alpha -1,4 lingages to a alpha -1, alpha -1 linkages; a process for producing the transferase; a gene coding for the same; and a process for producing an oligosaccharide by using the same. Also provided are a novel amylase that has a principal activity of acting on a saccharide, as a substrate, composed of at least three sugar units wherein at least three sugar units on the reducing end side are glucose units and the linkage between the first and the second glucose units is alpha -1, alpha -1 while the linkage between the second and the third glucose units is alpha -1,4 so as to liberate alpha , alpha -trehalose by hydrolyzing the alpha -1,4 linkage and another activity of hydrolyzing the alpha -1,4 linkage within the molecular chain of the substrate and that liberates dissaccharides and/or monosaccharides as the principal final products; a process for producing the amylase; a gene coding for the same; and a process for producing alpha , alpha -trehalose by using a combination of the transferase and the amylase.
    • 本发明提供了一种新的转移酶,其作用为由至少三个糖单元组成的作为底物的糖,其中还原末端侧的至少三个葡萄糖残基连接成α-1,4,以转移α-1, 4个碱基对α-1,α-1键; 生产转移酶的方法; 编码相同的基因; 以及使用该寡糖的方法。 还提供了一种新的淀粉酶,其具有作用于由至少三个糖单元组成的糖类作为底物的主要活性,其中还原端侧的至少三个糖单元是葡萄糖单元,第一和第 第二葡萄糖单位是α-1,α-1,而第二和第三葡萄糖单元之间的连接是α-1,4,以便通过水解α-1,4键和另一种活性来释放α,α-海藻糖 水解基质分子链内的α-1,4键,释放出脱糖和/或单糖作为主要的最终产物; 淀粉酶的制造方法; 编码相同的基因; 以及通过使用转移酶和淀粉酶的组合产生α,α-海藻糖的方法。
    • 28. 发明申请
    • DRUGS FOR AMELIORATING OPHTHALMIC CIRCULATORY DISTURBANCE
    • 用于改善眼底循环障碍的药物
    • WO1998029135A1
    • 1998-07-09
    • PCT/JP1997004665
    • 1997-12-17
    • KIRIN BEER KABUSHIKI KAISHAOGAWA, TakahiroWATANABE, NorikoWAKI, Mitsunori
    • KIRIN BEER KABUSHIKI KAISHA
    • A61K45/00
    • A61K31/4406A61K31/275A61K31/44
    • Drugs for ameliorating ophthalmic circulatory disturbance characterized by containing as the active ingredient potassium channel openers. As the potassium channel openers, use may be preferably mado of carboxyimidamide derivatives represented by general formula (I), acid-addition salts thereof or hydrates of the same, wherein each symbol is as defined in the specification. When dropped into eyes, in particular, drugs for ameliorating ophthalmic circulatory disturbance containing the compounds of general formula (I) can increase the blood flow in the optic papillae of normal eyes and inhibit retinal vessel contraction and a decrease in the blood flow in the optic papillae of eyes suffering from circulatory disturbance caused by ET-1 while scarcely affecting the blood pressure. It is therefore suggested that these compounds are useful as remedies for glaucoma, in particular, normotensive glaucoma caused by ophthalmic circulatory disturbance, retinal pigment degeneration, macular degeneration, ischemic optic nerve disease, iridocyclitis, retinal arterial obliteration, retinal phlebemphraxis, diabetic retinopathy, ischemic optic nerve disease, choroid diseases following retinal lesions, retinal choroid diseases accompanied by systemic diseases, etc.
    • 用于改善眼部循环障碍的药物,其特征在于含有作为活性成分的钾通道开放剂。 作为钾通道开放剂,可以优选使用通式(I)表示的羧酰亚胺酰胺衍生物,其酸加成盐或其水合物,其中每个符号如说明书中所定义。 特别地,当掉入眼睛时,特别是用于改善含有通式(I)化合物的眼科循环障碍的药物可以增加正常眼睛的视乳头中的血流量,并抑制视网膜血管收缩,并减少视神经中的血流量 患有ET-1引起的循环障碍的眼睛乳头,几乎不影响血压。 因此,认为这些化合物可用作青光眼的药物治疗,特别是由眼周循环障碍引起的血压正常的青光眼,视网膜色素变性,黄斑变性,缺血性视神经疾病,虹膜睫状体炎,视网膜动脉闭塞,视网膜血le症,糖尿病性视网膜病变,缺血性 视神经疾病,视网膜病变后的脉络丛疾病,伴有全身性疾病的视网膜脉络丛疾病等